204 results about "Doxorubicin Hydrochloride" patented technology

The invention relates to a method for preparing a graphene oxide double-targeting medicine carrier material, and a medicine loaded by the carrier material. The method is used for preparing the carrier material and the loaded medicine. The invention solves the problems that the conventional nano-medicine carrier has a complicated structure, is high in synthetic cost and low in efficiency, and cannot be massively prepared easily. The method for preparing the graphene oxide double-targeting medicine carrier material comprises the following steps of: preparing carboxymethylated graphene oxide; preparing a graphene oxide-biologically targeting molecule composite; and preparing the graphene oxide double-targeting medicine carrier material, wherein the loaded medicine is one or more of doxorubicin hydrochloride, paclitaxel, hydroxycamptothecine and daunomycin.

The present invention provides an acid sensitive doxorubicin prodrug based on polyethylene glycol, and a method and an application of the acid sensitive doxorubicin prodrug based on polyethylene glycol. The preparation method comprises: preparing a polyethylene glycol whose end contains an acid sensitive acetal group and a p-nitrophenyl ester azide group by a reaction of a polyethylene glycol whose double ends contain diazido ethyl diacetal groups with a p-nitro phenyl propargyl carbonate; preparing the acid sensitive doxorubicin prodrug based on the polyethylene glycol by the reaction of the prepared polyethylene glycol with doxorubicin hydrochloride. The acid sensitive and water soluble doxorubicin prodrug has good biocompatibility and acid sensitivity, thereby being used as a stimulation sensitive antineoplastic prodrug.

The invention relates to a passive targeting antitumor prodrug of solid tumor and a preparation method thereof, belonging to the field of antitumor drugs. The preparation method comprises the steps of: reacting small molecules of pectin with Mw of 5,000-45,0000 with doxorubicin to obtain pectin and doxorubicin conjugate with Mw of 100,000-1,000,0000, preparing a suspension, and processing the suspension by using a nano ultra high pressure homogenizing machine to obtain the passive targeting antitumor prodrug of solid tumor with particle diameter of 100-200 nm and melting point of 220-245 DEG C, wherein the pectin and the doxorubicin are connected by an amide bond, the pectin and the pectin are connected by an ester bond formed by condensing the carboxyl group and the hydroxyl group of pectin molecules. The cell inhibition rate of the antitumor prodrug to humanized lung carcinomas cells NCI-H446 and A549 is equivalent to that of the doxorubicin hydrochloride. In the research of the curative effect of melanoma B16 pulmonary metastasis mode mouse, the life cycle of mouse-borne tumor is 42.3+ / -12.4 days, which is remarkably higher than 23.1+ / -10.2 days of the doxorubicin hydrochloride group.

The invention provides a preparation method and application of a Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere. The preparation method comprises the following steps: preparing Fe2O3 nanoparticles by using a solvothermal method; under the condition that no surfactant is added and TEOS is used as a silicon source, preparing a Fe3O4@SiO2 composite microsphere with controllable morphology under mild conditions by using a combination of a template method and a hydrothermal method; corroding the Fe3O4@SiO2 composite microsphere with hydrochloric acid with a certain concentration so as to obtain a Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere; and carrying out reduction so as to prepare the Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere with superparamagnetism. The prepared Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere has a specific surface area of 173 m<2> / g and drug loading capacity of 139 mg / g; and with doxorubicin hydrochloride as a drug model, the Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere has a drug release rate of as high as 68.4% within 72 h in a PBS buffer solution with a pH value of 7.4, so the composite microsphere presents good slow drug release performance.

The invention relates to a new type of liver targeted drug carrier- glycyrrhetate modified chitosan / carboxylated chitosan compound drug carrier nanometer particle as well as its preparing method. The preparing procedure includes the following steps: dissolving the glycyrrhetate into carboxylated chitosan of a certain density; adding certain amount of chitosan solution which contains drug into the carboxylated chitosan while stirring; nanometer particles form automatically because of the electrostatic interaction among different molecules. The invention has simple preparing procedures, mile operating conditions and it has no poisoning or side effects of the organic solvents. Since the glycyrrhizin has characteristic of targeting at the liver, the product in the invention has the function of active targeting which leads to high effect liver targeting capabilities. The invention is applicable to the entrapment of medicine that contains electrical group (such as doxorubicin hydrochloride), protein drugs and medicine that has certain water-solubility in neutral pH conditions.

The invention provides a preparation method of a hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets. The preparation method comprises following steps: step 1, molybdenum disulfide nano tablets are obtained via hydro-thermal synthesis; step 2, the molybdenum disulfide nano tablets are added into a gelatin solution, and gelatinized molybdenum disulfide nano tablets are obtained via sufficient reaction; step 3, lactobionic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and N-hydroxy succinimide are weighed and added into the gelatinized molybdenum disulfide nano tablets so as to obtain lactobionic acid modified molybdenum disulfide nano tablets; and step 4, a doxorubicin hydrochloride aqueous solution is prepared, and the lactobionic acid modified molybdenum disulfide nano tablets obtained via step 3 are added into the doxorubicin hydrochloride aqueous solution, an obtained mixture is stirred for 8 to 24h under vacuum conditions, and is subjected to centrifugalization and washing so as to obtain the hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets via collecting. The hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets can be used for photothermal therapy and CT imaging, and can be used for realizing combination of diagnosis and treatment of hepatoma carcinoma.

The invention belongs to the field of biomedical materials, particularly relates to a preparing method of a core-shell structure drug carrier with near-infrared light exciting supermolecule valve light control drug release, and aims to solve the problems that a diagnosis and treatment agent cannot be controllably released in the aspects of time, space and dosage. The method includes the steps that upconversion nano particle cores are synthesized; upconversion nano particles with shells coated are synthesized; the outer layers of the upconversion nano particles are coated with mesoporous silica; the outer surfaces of the core-shell structure nano particles are modified with amino groups; surfactant is removed to form mesoporous; the outer surfaces of the core-shell structure nano particles are modified with guest molecules; doxorubicin hydrochloride is loaded, and pore passages are blocked. The core-shell structure drug carrier is used in cancer treatment, and timing and quantitative controlled release of anti-cancer drugs in tumor tissue is achieved.

The invention belongs to the field of preparation of biological medical materials, and relates to a method for preparing stable albumin nano-particles by virtue of thermal denaturation. The method comprises the following steps: (1) adding vanillic aldehyde or an analogue thereof to form intermolecular disulfide bonds by virtue of inter-reaction of free sulfhydryl groups on albumin molecules under a heating condition; (2) enabling amino groups inside and among molecules to react with carboxyl so as to form amido bonds; and (3) enabling amino groups on the albumin molecules to react with aldehyde groups on vanillic aldehyde or the analogue thereof to form chemical bonds of Schiff base and the like so as to form stable nano-particles in an aqueous solution. Any organic solvent is not introduced during preparation, so that the prepared nano-particles are safe and nontoxic, and can well entrap antitumor drugs including paclitaxel, doxorubicin hydrochloride and the like. Moreover, the carrier has an oxidation reduction response in a tumor cell internal environment, and can open disulfide bonds to release drugs under the action of reducing glutathione in cells. The method provided by the invention is simple in process, convenient to operate and suitable for industrial mass production.

The invention adopts the technical scheme that a doxorubicin hydrochloride-docetaxel or paclitaxel liposome preparation is provided. According to the technical scheme adopted by the invention, a water-soluble medicine and a fat-soluble medicine are encapsulated by liposome simultaneously; the water-soluble medicine is wrapped with the inner environment of the liposome; the fat-soluble medicine is wrapped between double layers of phospholipid membranes of the liposome; the water-soluble medicine is doxorubicin hydrochloride; and the fat-soluble medicine is docetaxel or paclitaxel. The doxorubicin hydrochloride-docetaxel or paclitaxel liposome preparation has the benefits that experiments prove that the toxic or side effect of the doxorubicin hydrochloride-docetaxel or paclitaxel liposome is obviously reduced and the anti-tumor therapy function of the doxorubicin hydrochloride-docetaxel or paclitaxel liposome is enhanced; the medicine encapsulation ratio of the liposome can reach 90% above; the result of the two-year stability experiment of the freeze-dried powder of the liposome at 2 to 8 DEG C below shows that the change rate of the average grain size is less than 6% and the change rate of the medicine encapsulation ratio is less than 5%, and shows excellent stability of the doxorubicin hydrochloride-docetaxel or paclitaxel liposome preparation.

The invention discloses enzymatic catalysis crosslinking reduction-responsive hyaluronic acid microgel and a preparation method thereof. The hyaluronic acid microgel is prepared by taking sulfhydrylation hyaluronic acid as a raw material, taking horseradish peroxidase as a catalyst, taking tyramine hydrochloride as an enzymatic catalysis reaction substrate and combining the method that horseradish peroxidase is catalytically crosslinked with sulfydryl to generate a disulfide bond through an inverse emulsion method. The disulfide bond crosslinking structure in the microgel can be broken in the presence of reductive substances such as dithiothreitol, reductive glutathione hormone and L-cysteine, and then the good reduction responsiveness is given to the microgel. The hyaluronic acid microgel can achieve controlled release on the reduction responsiveness of loaded doxorubicin hydrochloride and can be applied to controlled release of tumor-targeted drugs. According to the preparation method, a crosslinking agent does not need to be additionally added into an inverse emulsion system to cure the microgel, the toxicity influence of the crosslinking agent is avoided, the biocompatibility of the microgel is guaranteed, the reaction conditions are mild, and the technological processes are simple.

The invention relates to a doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel and a preparation method thereof. The doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel comprises chitosan, sodium beta-glycerophosphate, and polyethylene glycol with two ends respectively carrying a benzaldehyde group. The preparation method comprises the following steps: forming an imide bond with a self-healing performance through using a reaction of an amino group in the structure of chitosan and the benzaldehyde groups at two ends of the polyethylene glycol, combining the imide bond with chitosan / sodium beta-glycerophosphate temperature-sensitive gel, and loading doxorubicin hydrochloride into the obtained material through physical clathration to prepare the novel temperature-sensitive self-healing hydrogel administration system. The administration system is a liquid at room temperature, and rapidly gelates at a human body temperature after being injected to a tumor position in order to form a medicine reservoir ; and compared with traditional in situ gels, the temperature-sensitive self-healing hydrogel has the advantages of strong mechanical strength, realization of rapid self restoration under the action of outside force or tissue damages to avoid burst release of a medicine, further delay of release of the medicine and prolongation of the detention time of the medicine in the tumor position, medicine effect enhancement and reduction of toxic and side effects.

The invention relates to the field of biomedicine, in particular to a multi-functional bismuth selenide nanocomposite and a preparation method and application thereof. The multi-functional bismuth selenide nanocomposite aims to solve the problems that the synthesis condition and process of the existing hyperthermia chemotherapy nano material are complex, the biological safety is poor, the drug loading capacity is low, the existing hyperthermia chemotherapy nano material is short of an appropriate imaging diagnosis function, the heat-light properties need to be improved, and the existing hyperthermia chemotherapy nano material is short of clinical experimental verification. The grain size of the multi-functional bismuth selenide nanocomposite is 50 nm to 200 nm, and the drug loading capacity for loading doxorubicin hydrochloride is 3% to 10%. The preparation method comprises a step 1 of preparing Bi2Se3 nanosheets; a step 2 of preparing Bi2Se3@PDA nano particle dispersion liquid; and a step 3 of preparing the multi-functional bismuth selenide nanocomposite. The multi-functional bismuth selenide nanocomposite serves as the hyperthermia chemotherapy nano material to be utilized in hyperthermia chemotherapy of a malignant tumor or serves as a CT imaging contrast agent to be utilized in CT imaging diagnosis of the malignant tumor.

The invention discloses a synthetic method of a pH-response doxorubicin-dopamine conjugate and a prodrug nano particle thereof. The synthetic method comprises the steps of synthesizing a tertiary butyl-2-(3-(3,4-dihydroxyphenyl) propionyl) diamine carboxylic ester through 3,4-dihydroxyphenyl propionic acid; removing t-butyloxycarboryl through the tertiary butyl-2-(3-(3,4-dihydroxyphenyl) propionyl) diamine carboxylic ester for synthesizing 3-(3,4-dihydroxyphenyl) propanohydrazide; reacting the 3-(3,4-dihydroxyphenyl) propanohydrazide with doxorubicin hydrochloride for synthesizing a doxorubicin-dopamine conjugate molecule; synthesizing the doxorubicin-dopamine conjugate molecule and dopamine hydrochloride to obtain the doxorubicin-dopamine prodrug nano particle. Compared with the prior art, the invention provides a simple and effective way for preparing the doxorubicin-dopamine conjugate molecule and the doxorubicin-dopamine prodrug nano particle, and provides an experiment platform for obtaining a molecular drug carrier with integration of pH responsiveness, photothermal therapy and chemotherapy.

The invention discloses a doxorubicin hydrochloride light-controlled sustained-release liquid crystal gel preparation and a preparation method thereof. The light-controlled sustained-release liquid crystal gel preparation is prepared from 15-40 wt% of phospholipid, 60-70 wt% of glyceride, 1-20 wt% of a cosolvent, 0.01-2 wt% of doxorubicin hydrochloride and 0.001-0.2 wt% of a photosensitizer. The doxorubicin hydrochloride light-controlled sustained-release liquid crystal gel preparation has the advantages of low viscosity, good fluidity, easiness in injection, rapidness in formation of the liquid crystal gel after being injected into or around a tumor or being placed in a post-operative tumor cavity, and realization of in-situ slow release of doxorubicin hydrochloride; and lights cause phase change of the liquid crystal gel and increase the drug release rate, and the preparation prolongs the drug action time, reduces the administration frequency, reduces the toxic and side effects of the drug, releases the drug as needed by adjusting the release of the drug through adjusting the illumination frequency or time according to the tumor pathological conditions of a patient, and greatly improves the bioavailability of the drug.

The invention discloses a preparation method of modified carboxymethyl chitosan nano gel, belonging to the technical field of carriers and sustained-release material. The preparation method comprises the following steps: firstly preparing methylacryloyl carboxymethyl chitosan; and performing free radical polymerization in the presence of N'-N-bis(acrylyl) cystamine serving as a cross-linking agent to prepare the modified carboxymethyl chitosan nano gel. Through determining the particle size and zeta potential of nano particles under the condition of different pH values, the modified carboxymethyl chitosan nano gel is proved to have a pH sensitivity. A protein adsorption test shows that the nano gel is capable of preventing protein adsorption. The prepared nano gel is used for successfully carrying anticancer drug doxorubicin hydrochloride; in-vitro release tests in which PBS solutions different in pH and glutathione concentration are used as media prove that the drug-carried nano particles have relatively good pH and reduction sensitivity.

The invention discloses a doxorubicin hydrochloride liposome injection and a preparation technology thereof. The injection comprises the following components by weight percent: 0.05-0.5% of doxorubicin hydrochloride, 0.025-3% of hydrogenated soybean phosphatidylcholine, 0.001-1.5% of cholesterol, 0.01-1% of PEG-lipid, 0.0025-2.5% of organic acid or ammonium sulfate, 2.8-20% of sugar, 0.1-10% of buffering agent and the balance water for injection. The preparation technology comprises the following steps: 1) freeze-drying lipid phase; 2) hydrating lipid phase; 3) straightening the granules of lipid phase; 4) forming transmembrane gradient inside and outside phospholipid membrane; 5) loading medicine with liposome; and 6) degerming, subpackaging and storing.

The invention relates to a graphene oxide surface-enhanced Raman scattering positioning drug carrier and a preparation method thereof and one or more drugs carried by the graphene oxide surface-enhanced Raman scattering positioning drug carrier. The graphene oxide surface-enhanced Raman scattering positioning drug carrier utilizes a composite structure of graphene oxide and metal nanoparticles to carry a drug, utilizes surface-enhanced Raman scattering signals to trace a carrier position, and has a high drug carrying amount. A positively charged polymer modifies the surface of graphene oxide. The metal nanoparticles are gold nanorods. Raman molecules are adsorbed on the metal nanoparticles. The graphene oxide surface-enhanced Raman scattering positioning drug carrier solves the problem that the existing nano-drug carrier has a complex structure, a high synthesis cost and low efficiency and is difficult to industrialize. The preparation method comprises the following steps of graphene oxide preparation, graphene oxide-metal nanoparticle compound preparation, and graphene oxide drug carrier material preparation. The one or more carried drugs are selected from doxorubicin hydrochloride, 9-aminoacridine hydrochloride and hydroxycamptothecin.

The invention relates to applications of nicotinamide adenine dinucleotide in the field of pharmacy, and more specifically relates to applications of nicotinamide adenine dinucleotide in preparation of a medicine used for curing liver damages caused by chemotherapy drug doxorubicin hydrochloride. NAD<+> is capable of preventing and treating liver damages caused by chemotherapy drug doxorubicin hydrochloride effectively; and it is also found that NAD<+> is capable of killing glioma cells, neuronal tumor cells, gastric cancer cells, renal tumor cells or breast tumor cells effectively, but possesses no killing effect on normal primary cells.

The invention discloses natural polymer-poly(3-benzene acid acrylamide) composite nanospheres. The surfaces of the natural polymer-poly(3-benzene acid acrylamide) composite nanospheres are hydrophilic natural polymers; the interiors are hydrophobic poly(3-benzene acid acrylamide); the number average molecular weight of the natural polymer is in a range of between 2,000 and 100,000; the content ofthe natural polymer is 5 to 70 percent of the mass of the composite nanospheres; the number average molecular weight of the poly(3-benzene acid acrylamide) is in a range of between 1,000 and 10,000; the content of the poly(3-benzene acid acrylamide) is 30 to 95 percent of the mass of the composite nanospheres; and the average grain diameter of the composite nanospheres is of between 40 and 100 nanometers. The composite nanospheres of the invention have the characteristics of high biocompatibility and stable chemical properties. The composite nanospheres of the invention can be used as a medicament carrier, has a sustained-release effect, and can be used as a carrying agent in a boron neutron capture therapy. The invention also discloses a manufacturing method for the composite nanospheres.

The invention relates to an ATP responding type drug-releasing nano gel and a preparation method thereof, and belongs to the technical field of medicine. The nano gel is composed of carboxymethyl chitosan, DNA 1 with carboxyl modified terminals, DNA 2 with carboxyl modified terminals, and an ATP aptamer. Amino groups of carboxymethyl chitosan react with carboxyl groups of terminals of single chain DNA 1 and DNA2 to form stable amide bonds; because the ATP aptamer can carry out complementary base pairing with single chain DNA 1 and DNA2, the ATP aptamer can be used as a gel crosslinking agent, which can realize the crosslinking of nano gel; through physical embedding, doxorubicin hydrochloride is embedded in the GC segment of nucleic acid, the drug encapsulation is realized; and a novel ATP responding type drug-releasing nano gel drug delivering system is prepared. The system can respond to the high concentration ATP in tumor cell and competitively combines with the gel crosslinking agent (ATP aptamer); thus the complementarily paired nucleic acid chains are broken, the gel skeleton is broken, and drugs are released. The provided nano gel can improve the safety and targeting property of a tumor drug delivery system to a certain degree.

The invention relates to the field of medicinal preparations, in particular to a preparation method for a nanoliposome preparation of doxorubicin hydrochloride or doxorubicin. The preparation mainly comprises doxorubicin, egg yolk lecithin, cholesterol, an antioxidant, a buffer, sugar, injection water and the like. A preparation process comprises steps of preparation of blank liposome and doxorubicin nanoliposome, a process optimization step and the like. Freeze-dried powder prepared by the invention has high entrapment efficiency, high stability and a simple and practical preparation process.

The invention belongs to the technical field of medicine, in particular to an albumin-adriamycin nano preparation with double polysaccharide casing, a preparing method and application thereof. The nano preparation is the nano particle solution taking chitosan and glucan as the casing and taking albumin and adriamycin as the core. The preparing steps are as follows: mixing and heating chitosan andalbumin-glucan covalent compound to form the nano particle solution taking albumin as the core and taking glucan and chitosan as the casing; under the acidity condition, mixing the above nano particlesolution and doxorubicin hydrochloride solution; under certain pH value, covering adriamycin in the nano particle by diffusion. The tumor targeting ability of the albumin of the invention can improvethe curative effect of adriamycin and lower the toxic and side effect of adriamycin. The chitosan on the surface of the nano particle also has the function of resisting tumor and can strengthen immunity; glucan can prevent the nano particle from quickly clearing by macrophage so as to increase the chance for the nano particle to reach the tumor.

The invention discloses a doxorubicin hydrochloride-loaded self-healing hydrogel drug administration system and a preparation method thereof. The preparation method comprises the steps of oxidating pullulan into aldehyde-rich oxidated pullulan; by taking the oxidated pullulan, epsilon-polylysine, branched polyethyleneimine and doxorubicin hydrochloride as raw materials, performing Schiff base reaction in a water solution to form a dynamic imine bond cross-linked network, thus obtaining the self-healing hydrogel drug delivery system, wherein the doxorubicin hydrochloride is loaded into the system by two modes of dynamic imine bond cross linking and gel mesh adsorption. The preparation method is simple and easy to operate, the obtained hydrogel drug delivery system has good biocompatibility, biodegradability, temperature and pH sensitivity, self-sealing property and syringeability, and can be directly injected into a diseased region by tumor periphery injection drug administration without surgery implantation, thus greatly alleviating the pain of a patient, slowly releasing the doxorubicin hydrochloride in vivo, being beneficial to reducing of toxic and side effects of a drug, and achieving the aim of efficiently attenuating toxicity in a tumor treatment process.

The invention relates to a preparation method of a doxorubicin-containing graphene oxide medicine-carrying composite material. The preparation method comprises the following steps: (1) synthesizing a graphene oxide composite material GOX-PEI-HA; (2) dissolving the graphene oxide composite material into water, adding a doxorubicin hydrochloride aqueous solution, and regulating the pH to be neutral and alkaline; performing light-avoiding oscillating reaction; centrifugally removing disconnected DOX (Doxorubicin); and then freezing and drying to synthesize the GOX (Glucose Oxidase) / DOX medicine-carrying composition. The medicine-carrying material has the characteristic of pH sensitive releasing, can be applied to anti-tumor study, and has a high practical value.

The invention discloses a cell membrane microcapsule simultaneously loaded with a chemotherapeutic drug and a photodynamic therapeutic drug. Human cells are selected as a raw material for preparing the cell membrane microcapsule; the obtained cell membrane microcapsule is soaked into a digitonin solution to improve the permeability of cell membranes; a chemotherapeutic drug namely doxorubicin hydrochloride and a photodynamic therapeutic drug namely indocyanine green are added sequentially to ensure that the drugs are infiltrated into the cell membrane microcapsule; and calcium ions are used for sealing the cell membranes to obtain the cell membrane microcapsule simultaneously loaded with the chemotherapeutic drug and the photodynamic therapeutic drug. The cell membrane microcapsule can generate active oxygen under the irradiation of laser light of 808nm, and the active oxygen and the chemotherapeutic drug act together to kill tumor cells, so that the cell membrane microcapsule is expected to be used for tumor treatment. The preparation method of the cell membrane microcapsule disclosed by the invention is simple, convenient and controllable, is high in production efficiency and has good application prospects.

The invention belongs to the technical field of biomedicines, and particularly relates to a double-drug loaded thixotropic hydrogel for tumor local treatment and a preparation method thereof. The thixotropic hydrogel can be used for treating tumors by local injection including but not limited to intratumor injection, peritumoral injection and the like), and comprises the following components in percentage by mass: 1.2-18 percent of silk fibroin and 0.2-8 percent of hydroxy propyl cellulose, wherein the mass ratio of silk fibroin to hydroxy propyl cellulose is 1.5-9; and the anti-cancer medicament comprises 60-1900 mu g / mL curcumin and 10-3200 mu g / mL of doxorubicin hydrochloride. The drug loaded hydrogel has thixotropic syringeability and long-time drug sustained-release effect.

The invention relates to an oxidized graphene medicine-carried composite material for liver cancer targeting and a preparation method of the composite material. The obtained composite material is a compound formed by doxorubicin DOX and oxidized graphene GO-PEI-FI-PEG-LA which is modified by a lactobionic acid. The preparation method comprises the following steps: synthesizing the oxidized graphene composite material GO-PEI-FI-PEG-LA; preparing standard doxorubicin curves under the environment with two pH values; dissolving the oxidized graphene composite material in water, adding an aqueous solution of doxorubicin hydrochloride and regulating the pH value to obtain a neutral and alkaline value, stirring for 4 hours, dialyzing, freezing and drying so as to obtain the oxidized graphene medicine-carried composite material. The novel medicine-carried material provided by the invention has the characteristics of pH-sensitive releasing and liver cancer cell targeting, can be applied to anti-tumor researches and has a good practical value.

The invention provides a method for preparing keratin / hydroxyethyl methacrylate(HEMA) composite hydrogel of an interpenetrating polymer network structure. Natural polymer keratin and functional monomer hydroxyethyl methacrylate(HEMA) are used as raw materials, self-crosslinking polymerization is conducted under the action of a cross-linking agent and an initiating agent, and macromolecules in a composite hydrogel polymer are interpenetrated in different inlaid modes in three-dimensional space so that an interlaced network structure can be formed. The composite hydrogel has good swelling and deswelling properties, and further has pH sensibility. Vitro drug release experiments show that the composite hydrogel has a slow-release effect on small molecule compound rhodamine B, anti-cancer drug doxorubicin hydrochloride and macromolecular compound bovine serum albumin model drugs. Hence, the keratin / hydroxyethyl methacrylate(HEMA) composite hydrogel can be used as a drug carrier to be applied to a drug controlled release system.

The invention relates to the preparation of a magnetic nano-drug carrier and a method for using the magnetic nano-drug carrier to load doxorubicin hydrochloride, belonging to the technical field of magnetic nano-material drug transport. The invention mainly aims at solving the technical problems of high toxicity and poor treatment effect of the prior art. According to a technical scheme, a preparation method of the magnetic nano-drug carrier comprises the following steps: (1) preparing a cyclodextrin-hyaluronic acid supermolecule polymer; (2) preparing magnetic graphene oxide; (3) preparing the cyclodextrin-hyaluronic acid polymer-functionalized magnetic magnetic nano-drug carrier. Compared with the prior art, the magnetic nano-drug carrier is high in biocompatibility and low in toxicity,and has the characteristics of cancer cell targeted localization and drug controlled release, thus having an important application value in the aspect of biological drug carriers.

A doxorubicin and TRAIL co-supported albumin nanoparticle targeting preparation and a preparation method thereof. The preparation consists of doxorubicin hydrochloride DOX.HCl, human tumor necrosis factor apoptosis ligand TRAIL, bovine serum albumin BSA, polyethyleneimine PEI, carboxymethyl chitosan-folate conjugates CMCS-FA, water for injection and a crosslinking agent, and is a doxorubicin and TRAIL entrapped albumin nanoparticle targeting drug delivery system. The method comprises preparation of doxorubicin supported albumin nanoparticles, synthesis of a carboxymethyl chitosan-folate conjugate (CMCS-FA), and preparation of doxorubicin and TRAIL co-entrapped folate targeting albumin nanoparticles. Folic acid mediated active targeting and tumor pH sensitive release enhance the accumulation of drug carrier in tumors; the supported doxorubicin and TRAIL can produce synergistic anticancer effect and have a strong killing effect on cancer cells (including drug-resistant cells).